Aberrant expression of claudin‐6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma-Reference-Cited by-同舟云学术

Aberrant expression of claudin‐6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma

Published:2022-02-13 Issue:4 Volume:113 Page:1519-1530
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Ito Yui¹,Takasawa Akira¹^ORCID,Takasawa Kumi¹,Murakami Taro¹,Akimoto Taishi²,Kyuno Daisuke¹,Kawata Yuka¹,Shano Kodai¹,Kirisawa Kurara¹,Ota Misaki²,Aoyama Tomoyuki¹,Murata Masaki¹,Sugimoto Kotaro³,Chiba Hideki³,Saito Tsuyoshi²,Osanai Makoto¹^ORCID

Affiliation:

1. Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan

2. Department of Obstetrics and Gynecology Sapporo Medical University School of Medicine Sapporo Japan

3. Department of Basic Pathology Graduate School of Medicine Fukushima Medical University Fukushima Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15284

Reference63 articles.

1. Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries

2. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women

3. Adenocarcinoma: A unique cervical cancer

4. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England

5. The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multilayered proteomics reveals that JAM‐A promotes breast cancer progression via regulation of amino acid transporter LAT1;Cancer Science;2024-06-29

2. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6;Science Translational Medicine;2024-05-22

3. Claudins in Cancer: A Current and Future Therapeutic Target;International Journal of Molecular Sciences;2024-04-24

4. CLDN6 inhibited cellular biological function of nonsmall cell lung cancer cells through suppressing aerobic glycolysis via the RIP1/ASK1/JNK axis;Journal of Biochemical and Molecular Toxicology;2024-03

5. CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis;Cellular Signalling;2023-12